denotes an abstract that is clinically relevant.
denotes that this is a recommended PHD Trainee Session.
denotes that this is a ticketed session.
Program: Education Program
Session: How is the Management Paradigm Evolving for Hodgkin Lymphoma in 2023?
Hematology Disease Topics & Pathways:
Research, clinical trials, Hodgkin lymphoma, Biological therapies, adult, Clinical Practice (Health Services and Quality), Lymphomas, Non-Biological therapies, Clinical Research, Chimeric Antigen Receptor (CAR)-T Cell Therapies, Chemotherapy, Combination therapy, drug development, Diseases, Therapies, Immunotherapy, therapy sequence, Lymphoid Malignancies, Adverse Events, young adult , Natural Killer (NK) Cell Therapies, Radiation Therapy, Study Population, Human
Session: How is the Management Paradigm Evolving for Hodgkin Lymphoma in 2023?
Hematology Disease Topics & Pathways:
Research, clinical trials, Hodgkin lymphoma, Biological therapies, adult, Clinical Practice (Health Services and Quality), Lymphomas, Non-Biological therapies, Clinical Research, Chimeric Antigen Receptor (CAR)-T Cell Therapies, Chemotherapy, Combination therapy, drug development, Diseases, Therapies, Immunotherapy, therapy sequence, Lymphoid Malignancies, Adverse Events, young adult , Natural Killer (NK) Cell Therapies, Radiation Therapy, Study Population, Human
Saturday, December 9, 2023, 4:00 PM-5:15 PM
Disclosures: Grover: Tessa Therapeutics: Research Funding; Novartis: Honoraria; Sangamo: Current holder of stock options in a privately-held company; Seattle Genetics: Consultancy; Kite: Honoraria; ADC Therapeutics: Consultancy, Honoraria; Caribou Biosciences: Honoraria; Seagen: Honoraria; Genentech: Honoraria.
OffLabel Disclosure:
See more of: How is the Management Paradigm Evolving for Hodgkin Lymphoma in 2023?
See more of: Education Program
See more of: Education Program
<< Previous Presentation
|
Next Presentation